3 Rumors Pushing Around Stocks Today
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- AI stocks lift Wall St as oil falls, Treasury yields decline
- Oil prices slide to 11-day low on hopes of US-Iran diplomacy, Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- AI stocks lift Wall St as oil falls, Treasury yields decline
- Streamflation drives 39% of Americans to cancel streaming in 6 months
Jefferies sees up to 90% chance Horizon Therapeutics (HZNP) gets acquired, with $125 base case
December 1, 2022 11:06 AM ESTJefferies analyst Akash Tewari was the latest Wall Street analyst to weigh in on the takeover prospects of Horizon Therapeutics (NASDAQ: HZNP) after the company announced Tuesday that it is in preliminary talks with three large pharmaceutical companies about a potential buyout.
Tewari is positive on the prospects of a deal and sees one happening in the $25-$30 billion range, which he also said does not bake in Tepezza peak sales of $4 billion.
The analyst said the... More
Horizon Therapeutics seen worth up to $140/share in takeover
November 30, 2022 8:12 AM ESTSeveral Wall Street analysts put pencil to paper after Horizon Therapeutics (NASDAQ: HZNP) said Tuesday evening that it was in "highly preliminary" takeover talks with Amgen Inc. (NYSE: AMGN), Janssen Global Services, LLC (NYSE: JNJ), and Sanofi (NYSE: SNY). A deal price as high as $140 per share was the high watermark discussed by at least two analysts.
Cowen analyst Ken Cacciatore said that given their belief that Tepezza's previous pause was... More
